Cefalexin is the base drug of a large amount of antibiotic products related to the national economy and the people's livelihood in China, and occupies a large proportion in the pharmaceutical market in China and the world. The new round of competition elements in the field of API have gradually changed from the past capacity scale and cost competition to "green" competitiveness such as Waste minimisation, cleaner production processes and the resulting product quality superiority.
At present, the application capability of enzymatic technology is becoming a new competitive highland in the Chinese and foreign raw material drug markets. Compared to previous laboratory level technological research, the focus of competition today is on the research and development speed of key crystallization technologies for enzymatic technology products.
Due to the application of Immobilized enzyme, the organic solvent used in the reaction of Cefalexin enzyme synthesis is an aqueous phase, which greatly reduces the emission of VOC, which is beneficial to the previous process. However, due to the large changes in the system of the previous process, it poses a great challenge to the later crystallization; Due to the technological advancements of foreign manufacturers, the quality of competitors' products has also significantly improved, resulting in a significant increase in the current technical threshold.
Countries of interest: The
main problem that the UK plans to solve through the project: Cefalexin is a base drug for a large amount of antibiotic products in China, which is related to the national economy and the people's livelihood, and occupies a large proportion in China and the global pharmaceutical market. The new round of competition elements in the field of API have gradually changed from the past capacity scale and cost competition to "green" competitiveness such as Waste minimisation, cleaner production processes and the resulting product quality superiority.
At present, the application capability of enzymatic technology is becoming a new competitive highland in the Chinese and foreign raw material drug markets. Compared to previous laboratory level technological research, the focus of competition today is on the research and development speed of key crystallization technologies for enzymatic technology products.
Due to the technological advancements of foreign manufacturers, the quality of competitors' products has also significantly improved, resulting in a significant increase in the current technical threshold.